Using Mo7e-p210 and CD34+ cells from CML patients, we observed that in contrast to normal cells, a very low proportion of cells harboring the BCR/ABL oncogene generated FANCD2 nuclear foci, even after treatment with MMC (Figure 1). This evidence concerns the gene CD34 and chronic myelogenous leukemia, BCR-ABL1 positive.